Yousif Capital Management LLC Cuts Position in Bristol Myers Squibb Company $BMY

Yousif Capital Management LLC decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 4.0% in the 4th quarter, HoldingsChannel reports. The fund owned 212,722 shares of the biopharmaceutical company’s stock after selling 8,925 shares during the quarter. Yousif Capital Management LLC’s holdings in Bristol Myers Squibb were worth $11,534,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Kentucky Trust Co raised its position in Bristol Myers Squibb by 20.8% in the fourth quarter. Kentucky Trust Co now owns 10,242 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 1,767 shares in the last quarter. Clayton Financial Group LLC grew its holdings in Bristol Myers Squibb by 9.1% in the fourth quarter. Clayton Financial Group LLC now owns 5,343 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 447 shares during the last quarter. Cane Capital Partners LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at $526,000. Steadtrust LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at $633,000. Finally, Winthrop Advisory Group LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at $242,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Stock Up 2.6%

BMY opened at $59.20 on Thursday. The business’s fifty day simple moving average is $59.60 and its 200 day simple moving average is $52.98. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The firm has a market cap of $120.86 billion, a P/E ratio of 17.16, a PEG ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the previous year, the business posted $1.67 earnings per share. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BMY. Scotiabank reissued a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Citigroup upped their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their target price for the company from $52.00 to $61.00 in a report on Monday, December 15th. Barclays began coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $61.35.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.